S Y N O P S I S
No clear evidence of benefit from acupuncture in acute stroke
In China, acupuncture is used to treat many acute and chronic conditions, including stroke. We reviewed evidence from randomised controlled trials investigating acupuncture in patients with acute stroke, to determine whether acupuncture was safe, and whether it could reduce the number of patients who died, or were left needing help with everyday activities. The review showed no clear effect of acupuncture on either outcome. Serious adverse effects were uncommon, and occurred in about one in every hundred patients treated.
Results from much larger randomised trials are needed to assess accurately the benefits and harms of acupuncture in acute stroke.
B A C K G R O U N D
Stroke is the second leading cause of death in the world. In China, stroke is the second most common cause of death in cities, and the third most common cause of death in rural areas (MOH, PRC 2000) . Fifty per cent of survivors experience significant disability and 10% require long-term institutional care (DPH 1994) , which is a major burden for both family and society. Despite significant research efforts on pharmaceutical therapies for stroke, only aspirin and t-PA (used within three hours) show moderate benefit in acute ischaemic stroke (caused by a sudden blockage of an artery carrying blood to the brain); no specific therapies have been demonstrated to be effective in haemorrhagic stroke (caused by the bursting of a blood vessel in, or on, the brain). Therefore it is necessary to test other promising interventions including complementary medicines such as acupuncture, and Chinese herbal medicine.
Experimental data indicate that acupuncture-like sensory stimulation activates multiple efferent pathways (nerves carrying signals from the brain to muscles) that can lead to altered activity in numerous neural systems (Han 1982) . Whether spontaneous functional recovery after stroke can be enhanced by acupuncture has yet to be established.
Acupuncture has been used for hundreds of years in the treatment of acute stroke (Hu 1993) . It has been used by Chinese doctors to improve motor, speech and other function after stroke. In a recent survey, 66% of Chinese doctors used acupuncture for stroke routinely and 63% believed acupuncture to be effective. However about 36% thought the effectiveness of acupuncture was uncertain (Chen 1997a) . In China, acupuncture is a relatively simple and inexpensive treatment compared with many other commonly used interventions.
Acupuncture is well accepted by Chinese people and it is increasingly requested by patients and their relatives in some Western countries e.g. Sweden (Johansson 1993) . However, before acupuncture can be recommended for routine use in patients with stroke, rigorous randomised evidence should be provided to show its effectiveness. To date, randomised controlled trials of acupuncture in stroke have been reported both in, and outside, China. Two recent articles systematically reviewed trials on acupuncture for stroke (Park 2001; Sze 2002a) , one of them performed a metaanalysis (Sze 2002a). Both reviews included patients in the acute and chronic stages of stroke and did not show definite benefits of acupuncture. Whether or not acupuncture is effective for acute stroke alone is still unknown.
The aim of this review was to analyse systematically all the randomised controlled trials of acupuncture for acute stroke to provide the best available evidence for clinical practice and further research planning on stroke treatment.
O B J E C T I V E S
(1) To determine whether, in patients with acute ischaemic stroke or cerebral haemorrhage, acupuncture, compared with control, can increase the proportion of patients alive and not needing help in everyday activities without causing undue harm.
(2) To assess, in patients with acute ischaemic stroke or cerebral haemorrhage, the effects of acupuncture compared with control on impairment, quality of life and death from all causes.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W

Types of studies
Truly or quasi-randomised unconfounded controlled clinical trials comparing acupuncture with placebo, sham treatment or open control (no placebo) in patients with acute stroke were eligible for inclusion. Quasi-randomisation refers to allocation using alternate case record numbers, dates of birth or day of the week. Confounded trials in which the treatment or control group received another active therapy (e.g. acupuncture versus other intervention or acupuncture plus other intervention versus control) were excluded.
Types of participants
Trials which included patients of any age or sex with any type of acute stroke (within 30 days) were eligible. The diagnosis of stroke used should preferably be consistent with the WHO definition (a focal neurological impairment of sudden onset, and lasting more than 24 hours (or leading to death) and of presumed vascular origin) (Hatano 1976) . However, studies in which the diagnosis was based on purely clinical features or purely on brain imaging (computed tomography (CT) or magnetic resonance (MR) imaging) were also included. Trials restricted to patients with subarachnoid haemorrhage or subdural haematoma were excluded.
Types of intervention
Trials evaluating acupuncture treatment which involved needling and started within 30 days after stroke onset were included regardless of times of treatment and length of treatment period. Either traditional acupuncture, in which the needles are inserted in classical meridian points, or contemporary acupuncture, in which the needles are inserted in non-meridian or trigger points, were included regardless of the source of stimulation (e.g. hand or electrical stimulation). The control interventions could be placebo acupuncture, sham treatment or no treatment. When the addition of acupuncture to another treatment was compared to the other treatment alone and the trial was therefore assessing acupuncture, the trial was included. Placebo acupuncture refers to a needle attached to skin surface (van Tulder 2000) . Sham treatment refers to:
(1) needling prick on the skin surface (needles are placed in an area close to but not in acupuncture points) (van Tulder 2000); and (2) subliminal skin electrostimulation via electrodes attached to skin (Johansson 2001).
Types of outcome measures
Primary outcome measures included: (1) death or dependency at the end of follow up. In a subgroup analysis, the analyses were restricted to trials reporting on death or dependency at follow up at least three months after stroke. Dependency was defined as dependent on others in activities of daily living e.g. Barthel Index (BI) scored less than or equal to 60, modified Rankin Scale (MRS) grade 3 -6 (Sulter 1999), or trialists' own definition; (2) death or requiring institutional care (or requiring extensive family support) at the end of follow up (family care being the main form of care for severely dependent patients in developing countries). In a subgroup analysis, the analyses were restricted to trials reporting on institutional care/extensive family care at follow up at least three months after stroke; (3) adverse events: dizziness, difficulty in tolerating electrostimulation or pain, infection, puncture of a lung, heart tamponades (can precede heart failure), spinal cord injury, disrupted pacemaker function, and those effects presumed to have been caused by acupuncture and electrostimulation. The number of patients developing at least one of the severe adverse event listed above was evaluated.
Secondary outcome measures included:
(1) changes in neurological deficit score after acupuncture treatment and at the end of follow up (at three months or longer after stroke onset). The measures could focus on specific impairment (e.g. Motricity Index, or Motor Assessment Scale which assess only motor function) or global neurological deficit (e.g. the National Institute of Health Stroke Scale (NIHSS), Canadian Neurological Scale (CNS), European Stroke Scale (ESS) or the Scandinavian Stroke Scale (SSS) which involve motor, sensory and other impaired neurological function); (2) death from all causes within the first two weeks of treatment and during the whole follow-up period; (3) quality of life (QOL) if assessed by included trials. The following search strategies using a combination of controlled vocabulary and free text terms were used and were modified for the other databases: MEDLINE (Ovid), CINAHL (Ovid), Cochrane Controlled Trials Register. 1 exp cerebrovascular disorders/ 2 (stroke$ or poststroke$ or cva$).tw. 3 (cerebrovascular$ or cerebral vascular).tw. 4 (cerebral or cerebellar or brainstem or vertebrobasilar).tw. 5 (infarct$ or isch?emi$ or thrombo$ or apoplexy or emboli$).tw. 6 4 and 5 7 (cerebral or intracerebral or intracranial or parenchymal).tw. 8 (brain or intraventricular or brainstem or cerebellar).tw. 9 (infratentorial or supratentorial or subarachnoid).tw. 10 7 or 8 or 9 11 (haemorrhage or haemorrhage or hematoma or hematoma).tw. 12 (bleeding or aneurysm).tw. In addition, the reference lists of two recent systematic reviews (Park 2001; Sze 2002a ) and all identified trials were searched for relevant articles.
S E A R C H S T R A T E G Y F O R I D E N T I F I C A T I O N O F S T U D I E S
M E T H O D S O F T H E R E V I E W
Two authors (Zhang, Li) selected trials for inclusion in the review based on selection criteria outlined previously. Disagreement was resolved by discussion with a third party if necessary. Two authors (Zhang, Li) extracted data from each included trial for the methodological quality and outcome assessments. All the extracted data were cross-checked and differences were agreed by conferring with a third party if necessary. The authors of trials were contacted to provide missing data where possible.
Quality assessment
Quality assessment was made by establishing whether each included trial met the following internal validity criteria:
(1) method of randomisation (truly or quasi-randomised); (2) adequate allocation concealment; (3) blinding (both of participants and outcome assessors); (4) intention to treat (ITT) analysis; (5) number lost to follow up.
Quality assessment was performed by two independent reviewers (Zhang, Li) and disagreements reported to, and resolved by, a third party. These criteria did not form exclusion criteria and are described in the 'Characteristics of included studies' table. We planned to perform sensitivity analysis to assess the effect of including or excluding quasi-randomised trials, and the effect of including or excluding trials where placebo or sham treatment was not used for patients in the control group.
Data extraction
Data were extracted by the same two reviewers and all disagreements resolved by consensus or a third party when necessary. For dichotomous outcomes (death, death or dependency at the end of three months, continuing to require a high level of care, numbers experiencing adverse events) the number of participants experiencing the event and the total number of participants in each arm of the trial were recorded.
For continuous or long ordinal outcomes (impairment scales such as Motricity Index, MAS, and QOL measures) mean change and standard deviation of the change were extracted for each group along with the number in each group.
Data regarding the number of applications and the length of treatment period of acupuncture in each trial were extracted and reported in the 'Characteristics of included studies' table. If interventions showed significant heterogeneity, trials were analysed separately.
Data synthesis
Overall comparison was made between acupuncture and control (placebo/sham acupuncture and open control). Comparisons were also made between acupuncture and sham acupuncture, acupuncture and open control separately. In subgroup analysis we planned to compare: (1) effects in patients with ischaemic stroke and cerebral haemorrhage; (2) effects in patients with different time to start treatment (within 10 days and after 10 days from stroke onset); and (3) effects in patients with different stroke severity at baseline, stroke severity was determined by CNS, NIHSS, SSS, ESS or, where no common standard was available, by trialists' own definition.
Both relative and absolute risk reductions were calculated for each dichotomous outcome. Heterogeneity between trial results was tested using a standard chi squared test. The results were reported as odds ratios (OR) with corresponding 95% confidence intervals (CI) for dichotomous data using the Peto fixed-effect method (APT 1994) . For continuous data, weighted mean difference (WMD) was computed for outcomes measured on the same scale, and standardized mean difference (SMD) was calculated when the same outcome was measured on different scales (for example QOL).
D E S C R I P T I O N O F S T U D I E S
Forty-five potentially eligible trials were identified. Fourteen trials, including a total of 1208 patients, met our inclusion criteria. Twenty nine trials were excluded because:
(1) no usable data were available for analysis ( Missing data were collected through contact with all authors of included trial reports. Seven authors provided further information about their trials (Chen 1997; Gosman-Hedstrom 1998; Hopwood 2003; Johansson 1993; Johansson 2001; Si 1998; Yu 1993) . For details of each trial please see the 'Characteristics of included studies' table.
Of the 14 included trials, 10 were conducted in China (including Hong Kong and Taiwan), 3 in Sweden and 1 in the UK. Mean age of participants ranged from 58.6 to 77 years. More men than women were included in most trials (between 51-93% men in 12 trials, and 49-50% men in 2 trials). Two trials (Sze 2002; Wu 2002) included patients with ischaemic stroke and patients with haemorrhagic stroke (11% and 36% respectively). All other trials included patients with ischaemic stroke, but in two of them (Hopwood 2003; Johansson 1993) patients with haemorrhage cannot be completely ruled out as CT/MRI scan was performed in only 65.4% and 50% of patients, respectively.
Ten of the 14 trials included patients with moderate or severe stroke, in which the following inclusion criteria were used: (1) modified Edinburgh-Scandinavian Stroke Scale (MESSS, a commonly used Chinese scoring system including eight items (level of consciousness, gaze, facial paresis, language, walking ability, motor function of arms, legs and hands)) score greater than 18 (Jin 1999); All trials, with the exception of three (Cai 2002; Duan 1997; Jin 1999) , definitely excluded patients with coma or patients who were unable to cooperate during treatment and evaluation because of unconsciousness or severe aphasia or other disorders. Three trials excluded patients who were dependent before stroke onset ( Acupuncture was started within 10 days after stroke onset in 10 trials (Cai 2002; Chen 1997; Gosman-Hedstrom 1998; Hopwood 2003; Hu 1993; Huang 2002; Johansson 1993; Johansson 2001; Si 1998; Wu 2002) , 15 days in two trials (Sze 2002; Yu 1993) , four to seven days in one trial (Gosman-Hedstrom 1998), 30 days in one trial (Jin 1999) . One trial reported that it included patients with acute stroke but the exact time of randomisation or start of acupuncture was not reported (Duan 1997) . This trial has been included in the review -and similar trials identified in the future will also be included to avoid excluding some otherwise informative trials -a sensitivity analysis excluding them can be performed if necessary. All trials selected traditional Chinese acupoints, three trials used scalp acupuncture (Cai 2002; Duan 1997; Yu 1993) while two trials used body acupuncture (Chen 1997; Sze 2002) , and nine trials used both. There was variation in the number and sites of acupoints but DU20, GU20, GB7, LI11, SJ5 and ST36 were selected frequently. Pure manual stimulation was performed in six trials (Cai 2002; Chen 1997; Duan 1997; Huang 2002; Wu 2002; Yu 1993) Seven trials evaluated the effect of acupuncture on activities of daily living (ADL) at the end of follow up, in which changes of BI score were evaluated at the end of the treatment period in two trials (Sze 2002; Wu 2002) , 90 days in one trial (Hu 1993) , and one year in four trials (Gosman-Hedstrom 1998; Hopwood 2003; Johansson 1993; Johansson 2001) . Death was recorded in ten trials (Chen 1997; Gosman-Hedstrom 1998; Hopwood 2003; Hu 1993; Jin 1999; Johansson 1993; Johansson 2001; Si 1998; Sze 2002; Yu 1993) . Three trials described the distribution of stroke survivors in different living settings (home, rehabilitation unit, nursing or old people home, acute hospital) at 10 weeks, 3 and 12 months (Gosman-Hedstrom 1998; Hopwood 2003; Johansson 1993) . Adverse events related to acupuncture were recorded in nine trials (Chen 1997; Gosman-Hedstrom 1998; Hopwood 2003; Hu 1993; Johansson 1993; Johansson 2001; Si 1998; Sze 2002; Yu 1993) .
All trials measured the neurological deficits score at the end of the acupuncture treatment period, and four trials followed up this outcome further: at 90 days (Hu 1993) 
M E T H O D O L O G I C A L Q U A L I T Y
Most of the included trials were of poor quality. Three trials used computer-generated random numbers to allocate treatment (Gos 
R E S U L T S
Death or dependency at the end of follow-up Data for this outcome were available for four trials with a total of 373 patients (Gosman-Hedstrom 1998; Hopwood 2003; Johansson 1993; Johansson 2001) . All trials followed patients for one year. Dependency was defined as BI less than or equal to 60 (out of a potential total of 100) (Gosman-Hedstrom 1998; Johansson 1993; Johansson 2001) and BI less than or equal to 12 (out of a potential total of 20) (Hopwood 2003) . There was no significant heterogeneity among them (P = 0.46). There was a borderline significant trend for fewer patients being dead or dependent in the acupuncture group than in the control group (OR 0.66, 95% CI 0.43 to 0.99). This would be clinically important if confirmed as it is equivalent to 100 fewer dead or dependent patients per 1000 treated with acupuncture. When acupuncture was compared with placebo and open control separately, there was still a trend for fewer patients being dead or dependent in the acupuncture group, but the difference was non-significant (OR 0.67, 95% CI 0.40 to 1.12; OR 0.63, 95%CI 0.31 to 1.29 respectively).
Death or institutional care at the end of follow-up Three trials (Gosman-Hedstrom 1998; Hopwood 2003; Johansson 1993) described survival in different settings at the end of follow up (12 months). The numbers of patients living at home and needing extensive family support were not available. The numbers of patients living in rehabilitation units, nursing homes/old people's homes and acute hospitals were included in the analysis as numbers requiring institutional care. There was no significant heterogeneity among the three trials. Overall, there was a significant reduction in patients who were dead or needed institutional care in the acupuncture group than in the control group (OR 0.58, 95% CI 0.35 to 0.96). When acupuncture was compared with sham acupuncture the difference was still significant (OR 0.49, 95% CI 0.25 to 0.96). When acupuncture was compared with open control, the difference was not significant (OR 0.73, 95% CI 0.34 to 1.55).
Number with adverse events related to acupuncture treatment Nine trials recorded adverse events which were possibly related to acupuncture. Among the 386 patients who received acupuncture, only six reported moderate or severe adverse events (Gosman-Hedstrom 1998; Hopwood 2003 ; Hu 1993; Sze 2002) and three of them stopped acupuncture treatment (Gosman-Hedstrom 1998). In the control group, one patient was reported as having difficulty in tolerating sham acupuncture due to anxiety (GosmanHedstrom 1998). Therefore, the risk of severe adverse events with acupuncture was possibly less than 1.55%. The possible adverse events with acupuncture included difficulty in tolerating the stimulation due to uncomfortable pain and anxiety (Gosman-Hedstrom 1998), infection of arm (Gosman-Hedstrom 1998), dizziness (Hu 1993), and severe bruising of acupoints (two patients who received heparin or warfarin treatment) (Hopwood 2003; Sze 2002) .
Changes of global neurological deficit score at the end of treatment period and at the end of follow-up (more than three months) Ten trials measured this outcome at the end of the treatment period, however, mean and standard deviation of changes of global neurological score could be extracted in only six trials with total of 453 patients (Cai 2002; Duan 1997; Gosman-Hedstrom 1998; Huang 2002; Si 1998; Wu 2002) . There was significant heterogeneity among the six trials (P < 0.00001), which was possibly due to differences in measuring scales, times of evaluation from stroke onset, and control groups used. Overall, patients in the acupuncture groups recovered more quickly from neurological deficits than patients in the control groups -the difference reached statistical significance (SMD 1.17, 95% CI 0.30 to 2.04). However, when acupuncture was compared with sham acupuncture, the difference was not significant (SMD 0.01, 95% CI -0.55 to 0.57).
One trial (Gosman-Hedstrom 1998) measured this outcome at the end of follow up (more than three months) when there was no significant difference between the groups (WMD 0.29, 95% CI -3.36 to 3.94).
Changes of motor function score at the end of treatment period and at the end of follow up (more than three months) Four trials measured change of motor function score rather than global neurological deficits in stroke survivors (Hopwood 2003; Johansson 1993; Johansson 2001; Yu 1993) . There was significant heterogeneity among the four trials (p < 0.00001), which was also possibly due to different measures, different time of evaluation from stroke onset and different control group used. Overall, there was a non-significant trend in favour of acupuncture with more improvement of motor function (SMD 0.76, 95% CI -0.25 to 1.77). The difference reached statistical significance when acupuncture was compared with open control but did not when compared with sham acupuncture (SMD 1.67, 95% CI 0.76 to 2.58; SMD -0.12, 95% CI -0.41 to 0.17 respectively).
At the end of follow-up (more than 3 months), two trials (Hopwood 2003; Johansson 2001) provided data on motor function score, and there was no significant difference between the acupuncture and sham acupuncture groups (WMD -0.02, 95% CI -0.35 to 0.31).
Death within first two weeks and during whole follow-up period Ten trials provided data on death within the first two weeks, and no significant heterogeneity was found among them. There were fewer deaths in the acupuncture groups than in the control groups, but the difference was not significant and the confidence interval was wide due to the small number of events (OR 0.60, 95% CI 0.18 to 2.01). When acupuncture was compared with sham acupuncture and open control separately, no statistically significant difference was detected (OR 0.62, 95% CI 0.06 to 6.10; OR 0.60, 95% CI 0.14 to 2.47 respectively).
Data on death during whole follow-up period were also available for the same ten trials, and there was no significant heterogeneity among them. There was no difference in likelihood of death between the acupuncture group and the control group (OR 0.92, 95% CI 0.56 to 1.53). When acupuncture was compared with sham acupuncture and open control separately, no statistically significant difference was detected (OR 0.87, 95% CI 0.44 to 1.71; OR 1.00, 95% CI 0.47 to 2.14 respectively).
Quality of life (QOL) at the end of follow-up
Four trials evaluated QOL at the end of follow up (12 month). Since for most trials standard deviations of the Nottingham Health Profile (NHP) scores were not available, it was impossible to perform a meta-analysis. All trials showed non-significant differences in three dimensions of NHP (energy, pain and sleep) between the acupuncture groups and the sham acupuncture or no acupuncture groups. In another three dimensions of NHP (mobility, social isolation and emotion), one trial reported a significant difference in favour of acupuncture for improving mobility and emotion (Johansson 1993) , and another trial reported a significant difference in favour of acupuncture for improving social isolation. However, compared with two negative trials (Gosman-Hedstrom 1998; Johansson 2001), these two positive trials had smaller samples. Thus there is no definitive evidence from the current trials that acupuncture can improve long term QOL.
Subgroup analysis
As the number of trials and total number of patients included in the analysis for each outcome were small, we did not perform predetermined subgroup analysis based on types of stroke (ischaemic or haemorrhagic stroke), time of starting acupuncture and stroke severity.
Sensitivity analysis (1) Excluding trials without placebo or sham treatment used in the control group
Three trials were included in the analysis (Gosman-Hedstrom 1998; Hopwood 2003; Johansson 2001) . No significant effects of acupuncture were detected for all outcomes. However, there was still a trend towards fewer patients dying or being dependent (OR 0.75, 95% CI 0.47 to 1.21) and fewer patients dying or needing institutional care (OR 0.58, 95% CI 0.32 to 1.07) in the acupuncture groups than in the control groups at the end of follow up.
(2) Excluding quasi randomised trials
In the previous analysis, only one quasi-randomised trial (Si 1998) provided usable data for analysis (changes of global neurological deficit score at the end of treatment period). Excluding the data from this trial did not alter the result (SMD 1.21, 95% CI 0.20 to 2.22).
(3) Excluding trials in which exact time of starting acupuncture treatment was unclear
In the previous analysis, there was only one trial in which the exact time of starting acupuncture treatment was unclear (Duan 1997). Excluding the data from this trial (changes of global neurological deficit score at the end of treatment period) did not alter the result (SMD 1.00, 95% CI 0.05 to 1.95).
D I S C U S S I O N
Fourteen trials with total of 1208 patients were included in this review. Compared with two previous systematic reviews on acupuncture for stroke (Park 2001; Sze 2002a) , the present review included only patients in the acute stage of stroke, and five new trials were identified and included (Cai 2002; Hopwood 2003; Huang 2002; Wu 2002; Yu 1993) . However, there was still no clear evidence of benefit of acupuncture for stroke.
There was a borderline significant trend favouring acupuncture with fewer patients being dead or dependent at the end of longterm follow up. It should be noted that the result was based on data from four trials with a limited number of patients (total of 373 patients). Further, of the four trials, only three were of high quality with regard to allocation concealment, blinding of assessment, and intention to treat (ITT) analysis. There is now empirical evidence of bias in studies with inadequately or unclearly concealed treatment allocation. Schulz et al (Schulz 1995) found that odds reductions were exaggerated by up to 30% for trials that did not have clear concealment, and by 41% for inadequately concealed trials. ITT analysis has been considered as an important strategy in pragmatic randomised controlled trials for assuring two main purposes: (1) maintains treatment groups that are similar; and (2) it allows for non-compliance and deviations from policy by clinicians (Hollis 1999 ). An analysis including only the three trials assessed as being of high quality did not show a significant effect of acupuncture. Thus, the apparent benefit of acupuncture may be merely due to the play of chance, imbalance of stroke severity at baseline or other methodological weaknesses. However, if the effect is real, the lack of statistical significance is almost certainly due to the small number of patients included -much larger samples would be needed to detect moderate effects of this size with any reliability.
For reasons similar to those above, the apparent effects of acupuncture in reducing death or institutional care and improving global neurological deficits were also unreliable and need to be verified in future trials.
It is desirable to perform both blinding of patients and blinding of outcome assessors in acupuncture trials since a large number of therapeutic sessions in the acute or subacute phase of stroke may have unspecific beneficial effects on recovery and quality of life. For cultural reasons, it was possible to use sham acupuncture in the two Sweden trials (Gosman-Hedstrom 1998; Johansson 2001) but it may be more difficult to perform it in other countries where patients are well acquainted with acupuncture and recognise the special sensation of 'Teh Chi' (e.g. in China). A recent systematic review suggested that placebos had no significant effects on objective or binary outcomes in clinical trials (Hrobjartsson 2001) . In this review, when acupuncture was compared with sham acupuncture and open control separately, it seems that there was a placebo effect of acupuncture on the global neurological deficits score, but not on death or dependency, or death or institutional care. Therefore, in future trials, objective or binary outcomes and blinding of outcome assessors should be used where possible. Placebo treatments may not be universally acceptable, but, in settings where they are acceptable, they should be used.
Although fourteen trials were included in this review, and half of them measured ADL using BI, none used death or dependency as a primary outcome. In future acupuncture trials, widely-applied, reliable and valid outcome measures should be used in order to facilitate a meta-analysis. It has been recommended that measures of the level of activity (disability or dependence) should be the most important primary outcome assessed in stroke trials, and that outcome assessment should be undertaken at six months or longer from the start of treatment (Duncan 2000).
Acupuncture appears to be a safe treatment when used in the acute phase of stroke, with severe adverse events occurring only very rarely (possibly less than 1.5%). However, it should be remembered that this result is not based on all included patients. Five of the included trials did not report adverse events. It was possible that authors only reported positive effects without reporting adverse events as well.
None of the included trials specifically assessed the effects of acupuncture on patients with haemorrhagic stroke. Two trials (Sze 2002; Wu 2002 ) included a few patients with haemorrhagic stroke (11%, and 36% respectively). As these two trials contributed little usable data to the analysis, the present review actually assessed the effects and adverse events of acupuncture on ischaemic stroke. Therefore, more trials of acupuncture for haemorrhagic stroke are required in future.
The ongoing trial (AAIST 2001), using disability and long-term institutionalisation as primary outcomes, will provide further data on the effectiveness of acupuncture for acute ischaemic stroke.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The current evidence presented in this review does not support the routine use of acupuncture for patients with acute stroke.
Implications for research
As there appears to be an indication that acupuncture is potentially effective and safe in the treatment of acute ischaemic stroke, further well-designed trials are required to confirm or refute this. The trial that is currently ongoing should proceed as rapidly as possible and publish its findings as soon as possible. There is also a need to conduct more randomised controlled trials of acupuncture in haemorrhagic stroke. Future trials should overcome the limitations of many of the trials presented in this review. In particular, they should ensure adequate concealment of allocation and blinding of outcome assessors, use an objective dichotomous functional outcome as a primary outcome, have long-term follow-up, and publish the results in a usable form to facilitate a meta-analysis.
P O T E N T I A L C O N F L I C T O F I N T E R E S T
None known.
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Characteristics of excluded studies
Cai 2002a
Questionable randomisation (patients in five hospitals were included, but patients in one hospital only were allocated into the control group).
Fu 2001
Data from this trial were questionable (data were inconsistent in full text of published paper)
Jiang 1998
It was not possible to include data from this trial in the analysis. MESSS was assessed before and after treatment period, but mean change of MESSS score was not available.
Li 1989
The trial aimed to assess effects of two kinds of acupuncture on acute stroke (acupuncture involving Du15 and Du16 in addition to other acupoints versus acupuncture involving other acupoints alone).
Li 1999
It was not possible to include data from this trial in the analysis (see reason for exclusion of Jiang 1998).
Li 2000a
Li 2000b
Li 2001
Liu 2001
Liu 2002a
It was not possible to include data from this trial in the analysis. Motor function and BI were assessed before and after treatment period, but mean change of motor function score and number of patients being independent after treatment period were not available.
Liu 2002b
It was not possible to include data from this trial in the analysis. MESSS scores, motor function and BI were assessed before and after treatment period, but mean change of neurological score and number of patients being independent after treatment period were not available.
Liu 2003
It was unclear when acupuncture treatment was started after stroke onset.
Lv 2003
It was not possible to include data from this trial in the analysis. Motor function was assessed before and after treatment period, but mean change of motor function score after treatment period was not available.
Ma 1999
Confounded (acupuncture versus nimodipine), questionable randomisation (68 cases in acupuncture group and 30 cases in control group).
Pei 2001
Confounded (clinical treatment plus electro-acupuncture versus clinical treatment plus active and/or passive functional exercise).
Tang 1996
Wang 2001 It was not possible to include data from this trial in the analysis. Neurological score was assessed using a scoring system based on principles of traditional Chinese medicine, but mean change of score after treatment period was not available.
Wong 1999 Acupuncture points were stimulated by using adhesive surface electrode.
Xu 1997
It was not possible to include data from this trial in the analysis. BI was assessed before and after treatment period, but number of patients being independent at the end of treatment period was not available.
Xu 2001
It was not possible to include data from this trial in the analysis. MESSS scores, motor function and BI were assessed before and after treatment period, but mean change of neurological score and numbere of patients being independent after treatment period were not available.
Yang 2001
Yu 2003
Data f rom this trial were questionable. Patients with acute ischemic stroke and BI < 70 were included and randomised in outpatients' department. It was difficult to perform this trial in China.
Yun 2000 Confounded (acupuncture plus defibrase (5 U) versus defibrase (10 U)).
Zhang 1996 It was not possible to include data from this trial in the analysis (see reason for exclusion of Jiang 1998).
DOI
10.1002/14651858.CD003317.pub2
Cochrane Library number CD003317
Editorial group Cochrane Stroke Group
Editorial group code HM-STROKE Fig. 1 
G R A P H S A N D O T H E R T A B L E S
